Focused ultrasound-enabled brain tumor liquid biopsy (FUS-LBx) supplement

聚焦超声脑肿瘤液体活检 (FUS-LBx) 补充剂

• 批准号: 10448708
• 负责人: Hong Chen
• 金额: $ 13.54万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-19 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10448708
• 关键词: Address; Animals; Applications Grants; Automobile Driving; Biological Markers; Biopsy; Blood; Blood - brain barrier anatomy; Blood Circulation; Brain; Brain Diseases; Brain Neoplasms; Cardiovascular system; Clinical; Clinical Management; DNA; Data; Detection; Development; Devices; Diagnosis; Disease; Excision; Family suidae; Focused Ultrasound; Future; Goals; Histologic; Image; Learning; Liquid substance; Location; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of brain; Medical; Microbubbles; Molecular; Molecular Profiling; Monitor; National Institute of Biomedical Imaging and Bioengineering; Operative Surgical Procedures; Parents; Patient Monitoring; Patients; Polymerase Chain Reaction; Proteins; Public Health; RNA; Research; Risk; Sampling; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Spectrum Analysis; Techniques; Tissues; Tumor Markers; Tumor-Derived; United States; United States National Institutes of Health; Work; base; clinical translation; commercialization; controlled release; design; detection method; digital; extracellular vesicles; liquid biopsy; neoplastic cell; neuroimaging; next generation sequencing; novel; patient population; pre-clinical; programs; safety and feasibility; tool; treatment response; tumor; tumor progression

PROJECT SUMMARY/ABSTRACT This application is for the NIBIB C3i Accell program. The objective of our parent R01 application (R01EB030102, Project Period: 08/01/2020–04/30/2024) is to perform small animal and large animal studies to obtain compelling preclinical evidence needed to support future clinical translation of focused ultrasound-enabled liquid biopsy (sonobiopsy). Through learnings from NIBIB’s C3i programs, we identified that one key risk toward commercialization of our technique is the need to optimize the design of the sonobiopsy device for clinical use and validated its feasibility and safety in biomarker release. The objective of our proposed research for the C3i Accell program is to address this key technical risk. Successful completion of this work will obtain data that will support our start-up company’s NIH SBIR/STTR grant application to further commercial development efforts.

项目概要/摘要 该应用程序适用于 NIBIB C3i Accell 程序。我们父级 R01 应用程序的目标 （R01EB030102，项目期间：08/01/2020–04/30/2024）将进行小动物和大型动物研究 获得支持聚焦超声未来临床转化所需的令人信服的临床前证据 液体活检（超声活检）。通过从 NIBIB 的 C3i 项目中学习，我们发现了一个关键风险 为了实现我们技术的商业化，需要优化声活检设备的设计 用于临床并验证其在生物标志物释放中的可行性和安全性。我们提议的目标 C3i Accell 计划的研究就是为了解决这一关键技术风险。这项工作的顺利完成将 获取数据支持我们的初创公司的 NIH SBIR/STTR 拨款申请以进一步商业化 发展努力。